Korro Bio Inc KRRO

$13.67 +0.37 (2.78%)

Valuation

Market cap
177,006,000
Revenue TTM
$6,390,000
Net income TTM
$-117,260,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,835.05%
Debt to equity
0.00

Trading

Volume
180,070
Avg volume
174,612
Day's range
$13.04 – $14.11
Shares out
14,726,000
Stochastic %K
88%
Beta
3.13
Analysts
Strong Sell
Price target
$20.00

Price

Company profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA ed...

Show more

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 468 1999
Website
https://www.korrobio.com
Address
60 First Street, 2nd Floor Suite 250, Cambridge, United States

Latest news

Stocktwits

Benny_Cellura Oct 28, 9:04 AM 0 replies
ajmrtxl Oct 27, 4:13 PM
$KRRO 's latest squeeze play
0 replies
Merlintrader Oct 27, 12:09 PM
$KRRO finished Monday at $12.02, above both the 50-day SMA ($11.35) and the 200-day ($11.56), near the top of its 20-day range ($8.34-$12.49). Daily RSI 62. Bull and bear scenarios, support/resistance and trendlines on the interactive JC Just Charts page: https://justcharts.merlintrader.com/#KRRO Not investment advice.
0 replies
PhishTourFunds Oct 27, 5:27 AM
$KRRO +20%
0 replies
PhishTourFunds Oct 23, 2:40 AM
$KRRO 6+ got-damn months nah…
0 replies
Merlintrader Oct 22, 9:39 PM
$KRRO Latest company news, Oct 22, 2026: Korro Bio reported preclinical KRRO-111 data in alpha-1 antitrypsin deficiency, with up to 96% SERPINA1 mRNA editing and up to a 95% drop in liver Z-AAT in mouse models. A regulatory submission and clinic entry are expected in H1 2027. Full hub (KRRO-121, KRRO-111, cash): https://www.merlintrader.com/korro-bio-stock-hub/ Not investment advice.
0 replies
topstockalerts Oct 22, 8:04 PM
$KRRO this one is doing a lot with very little noise.
0 replies
Paul_Laurent Oct 22, 7:39 PM
📊🔥 Top Gainers Update 💰🚨 RTH 3:38pm ET Focusing on movers with the strongest fresh catalysts: $STAK +58.50% – FY2026 revenue increased 13.2% to $28.2M, while STAK swung from a $5.7M loss to ~$426K net income, driven by sharply stronger specialized oilfield-vehicle sales. $SHFS +135.34% – Continued momentum after Nasdaq granted Safe Harbor an additional 180 days, through April 19, 2027, to regain minimum-bid compliance. $CRMT +53.04% – America’s Car-Mart is reportedly working with senior lenders toward a potential sale of the company as it navigates severe liquidity and debt pressures. $VIVK +25.60% – Fresh catalyst: Vivakor received approval of its P-5 Organization Report, advancing its Houston-area Remediation Processing Center toward targeted Q1 2027 operations. $KRRO +25.51% – Fresh biotech catalyst after Korro Bio reported preclinical KRRO-111 data for alpha-1 antitrypsin deficiency, supporting development of its next-generation RNA-editing program.
0 replies